

Appl. No. : 10/063,617
Filed : May 3, 2002

AMENDMENTS TO THE CLAIMS

1-3. (Canceled).

4. (Currently Amended) ~~The An isolated polypeptide of Claim 1~~ having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110);

(b) the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110), lacking its associated signal peptide; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 110 (SEQ ID NO: 110);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 110 (SEQ ID NO: 110), lacking its associated signal peptide; or~~

~~(c)(e)~~ the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203535;

wherein said isolated polypeptide is more highly expressed in esophageal tumor tissue compared to normal esophageal tissue, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in esophageal tumor tissue compared to normal esophageal tissue.

5. (Currently Amended) The isolated polypeptide of ~~Claim 1~~ Claim 4 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110);

(b) the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110), lacking its associated signal peptide; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 110 (SEQ ID NO: 110);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 110 (SEQ ID NO: 110), lacking its associated signal peptide; or~~

~~(c)(e)~~ the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203535;

Appl. No. : 10/063,617
Filed : May 3, 2002

wherein said isolated polypeptide is more highly expressed in esophageal tumor tissue compared to normal esophageal tissue, or wherein said isolated polypeptide is encoded by a polynucleotide that is more highly expressed in esophageal tumor tissue compared to normal esophageal tissue.

6. (Currently Amended) An isolated polypeptide comprising:

(a) the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110);

(b) the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110), lacking its associated signal peptide; or

~~(c) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 110 (SEQ ID NO: 110);~~

~~(d) the amino acid sequence of the extracellular domain of the polypeptide shown in Figure 110 (SEQ ID NO: 110), lacking its associated signal peptide; or~~

(c)(e) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203535.

7. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110).

8. (Currently Amended) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide of shown in Figure 110 (SEQ ID NO: 110), lacking its associated signal peptide.

9-10. (Canceled).

11. (Original) The isolated polypeptide of Claim 6 comprising the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203535.

12. (Currently Amended) A chimeric polypeptide comprising a polypeptide according to ~~Claim 1~~ Claim 4 fused to a heterologous polypeptide.

13. (Currently Amended) The chimeric polypeptide of Claim 12, wherein said heterologous polypeptide is ~~an epitope~~ a tag polypeptide or an Fc region of an immunoglobulin.

14. (New) An isolated polypeptide having at least 95% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 110;

Appl. No. : 10/063,617
Filed : May 3, 2002

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 110, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203535;

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 110 in esophageal tissue samples.

15. (New) The isolated polypeptide of Claim 14 having at least 99% amino acid sequence identity to:

(a) the amino acid sequence of the polypeptide of SEQ ID NO: 110;

(b) the amino acid sequence of the polypeptide of SEQ ID NO: 110, lacking its associated signal peptide; or

(c) the amino acid sequence of the polypeptide encoded by the full-length coding sequence of the cDNA deposited under ATCC accession number 203535;

wherein said isolated polypeptide or a fragment thereof can be used to generate an antibody which can be used to specifically detect the polypeptide of SEQ ID NO: 110 in esophageal tissue samples.

16. (New) A chimeric polypeptide comprising a polypeptide according to Claim 14 fused to a heterologous polypeptide.

17. (New) The chimeric polypeptide of Claim 16, wherein said heterologous polypeptide is a tag polypeptide or an Fc region of an immunoglobulin.

Appl. No. : **10/063,617**
Filed : **May 3, 2002**

DELETION OF INVENTORS

Please correct the inventorship under 37 CFR §1.48(b) by removing the following inventors from the present application:

Dan L. Eaton, Ellen Filvaroff, Mary E. Gerritsen, and Colin K. Watanabe.

Applicants request that these inventors be deleted, as their inventions are no longer being claimed in the present application as a result of prosecution.